cefepime Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	535	88040-23-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefepime dihydrochloride hydrate cefepime cefepime hydrochloride cefimen tsefepim cefepime HCl	A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA. Molecular weight: 480.56 Formula: C19H24N6O5S2 CLOGP: -5.97 LIPINSKI: 1 HAC: 11 HDO: 2 TPSA: 150.04 ALOGS: -4.49 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefepime dihydrochloride hydrate
cefepime
cefepime hydrochloride
cefimen
tsefepim
cefepime HCl

A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.

Molecular weight: 480.56
Formula: C19H24N6O5S2
CLOGP: -5.97
LIPINSKI: 1
HAC: 11
HDO: 2
TPSA: 150.04
ALOGS: -4.49
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
4	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	85 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.28 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.20 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.78 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.90 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 18, 1996	FDA	HOSPIRA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	366.05	17.98	263	12987	94364	46578448
Encephalopathy	273.66	17.98	150	13100	33439	46639373
Acute kidney injury	259.60	17.98	326	12924	235529	46437283
Status epilepticus	158.51	17.98	78	13172	13901	46658911
Sepsis	147.49	17.98	187	13063	135827	46536985
Neurotoxicity	145.06	17.98	73	13177	13644	46659168
Pyrexia	138.82	17.98	305	12945	348497	46324315
Drug reaction with eosinophilia and systemic symptoms	120.48	17.98	85	13165	29463	46643349
Cytokine release syndrome	105.79	17.98	46	13204	6177	46666635
Tubulointerstitial nephritis	101.26	17.98	59	13191	14729	46658083
Myoclonus	97.58	17.98	57	13193	14295	46658517
Septic shock	88.36	17.98	95	13155	57798	46615014
Thrombocytopenia	80.02	17.98	135	13115	126446	46546366
Mental status changes	77.39	17.98	73	13177	38015	46634797
Pneumonia	71.94	17.98	252	12998	376068	46296744
Respiratory failure	69.24	17.98	108	13142	94708	46578104
Multiple organ dysfunction syndrome	67.13	17.98	78	13172	51632	46621180
Pain	63.68	17.98	28	13222	476920	46195892
Arthralgia	57.90	17.98	16	13234	364587	46308225
Pathogen resistance	57.52	17.98	30	13220	6030	46666782
Neutrophil count decreased	57.19	17.98	66	13184	43360	46629452
Renal tubular necrosis	55.92	17.98	36	13214	10723	46662089
Klebsiella infection	54.85	17.98	30	13220	6632	46666180
Fatigue	53.06	17.98	57	13193	608640	46064172
Clostridium difficile colitis	52.62	17.98	43	13207	18510	46654302
Platelet count decreased	50.76	17.98	97	13153	99927	46572885
Rheumatoid arthritis	50.26	17.98	5	13245	240210	46432602
Cytomegalovirus test positive	48.43	17.98	21	13229	2799	46670013
Neutropenia	46.52	17.98	116	13134	143088	46529724
Hypoxia	46.38	17.98	65	13185	51773	46621039
Toxic encephalopathy	45.03	17.98	24	13226	5038	46667774
Drug resistance	44.58	17.98	38	13212	17330	46655482
Bacteraemia	42.62	17.98	34	13216	14145	46658667
Confusional state	41.31	17.98	119	13131	159773	46513039
Dizziness	40.81	17.98	23	13227	340391	46332421
Nephropathy toxic	38.88	17.98	25	13225	7429	46665383
Renal impairment	38.79	17.98	73	13177	74299	46598513
Pancytopenia	37.73	17.98	78	13172	84980	46587832
Malaise	37.43	17.98	24	13226	331208	46341604
Headache	36.10	17.98	50	13200	478302	46194510
Trichosporon infection	34.70	17.98	9	13241	240	46672572
Clostridium difficile infection	34.46	17.98	39	13211	25064	46647748
Product dose omission issue	33.98	17.98	4	13246	168516	46504296
Nephritis allergic	33.08	17.98	8	13242	159	46672653
Metabolic encephalopathy	32.91	17.98	20	13230	5383	46667429
Alopecia	32.38	17.98	4	13246	162410	46510402
Toxic epidermal necrolysis	31.25	17.98	35	13215	22243	46650569
Cytomegalovirus viraemia	30.99	17.98	18	13232	4460	46668352
Enterococcal bacteraemia	30.81	17.98	12	13238	1217	46671595
Enterococcal infection	30.56	17.98	21	13229	6966	46665846
Differentiation syndrome	30.52	17.98	11	13239	900	46671912
Nasopharyngitis	30.20	17.98	4	13246	153994	46518818
Aspartate aminotransferase increased	30.12	17.98	68	13182	78632	46594180
Abdominal discomfort	29.47	17.98	4	13246	151161	46521651
Blood creatinine increased	29.22	17.98	66	13184	76337	46596475
Acute generalised exanthematous pustulosis	29.22	17.98	23	13227	9382	46663430
Anaemia	28.81	17.98	146	13104	255633	46417179
Respiratory distress	28.50	17.98	40	13210	31876	46640936
Hypertensive heart disease	28.06	17.98	14	13236	2564	46670248
Dysbiosis	27.78	17.98	9	13241	533	46672279
Cholestatic liver injury	27.73	17.98	13	13237	2077	46670735
Toxic skin eruption	27.58	17.98	25	13225	12362	46660450
White blood cell count decreased	27.49	17.98	82	13168	112149	46560663
Bronchopulmonary aspergillosis	26.96	17.98	20	13230	7476	46665336
Graft versus host disease	26.94	17.98	19	13231	6569	46666243
Hypotension	26.35	17.98	133	13117	232456	46440356
Immune effector cell-associated neurotoxicity syndrome	25.60	17.98	9	13241	685	46672127
Renal failure	25.03	17.98	80	13170	113514	46559298
Acute respiratory distress syndrome	25.03	17.98	31	13219	21891	46650921
Hyperoxaluria	24.77	17.98	6	13244	120	46672692
Agranulocytosis	24.73	17.98	31	13219	22154	46650658
Klebsiella bacteraemia	24.34	17.98	10	13240	1166	46671646
Aphasia	24.32	17.98	35	13215	28532	46644280
Weight decreased	24.16	17.98	15	13235	210834	46461978
Drug intolerance	24.15	17.98	6	13244	147043	46525769
Gait disturbance	23.71	17.98	6	13244	145257	46527555
Acute graft versus host disease in skin	23.37	17.98	13	13237	2969	46669843
Hyperbilirubinaemia	23.10	17.98	21	13229	10417	46662395
Engraft failure	22.50	17.98	7	13243	363	46672449
Chemotherapeutic drug level increased	22.49	17.98	6	13244	179	46672633
Acute respiratory failure	22.36	17.98	34	13216	29104	46643708
Respiratory alkalosis	22.25	17.98	12	13238	2579	46670233
Fungaemia	22.23	17.98	11	13239	1980	46670832
Hepatic function abnormal	22.07	17.98	37	13213	34384	46638428
Disseminated intravascular coagulation	21.90	17.98	27	13223	18978	46653834
Rash pustular	21.64	17.98	17	13233	6912	46665900
Peripheral swelling	21.45	17.98	9	13241	158062	46514750
Osteomyelitis	21.41	17.98	29	13221	22354	46650458
Fall	21.34	17.98	38	13212	329059	46343753
Antibiotic level above therapeutic	20.94	17.98	6	13244	234	46672578
Electroencephalogram abnormal	20.59	17.98	13	13237	3741	46669071
Muscle spasms	20.25	17.98	5	13245	123108	46549704
Encephalitis Japanese B	20.24	17.98	4	13246	29	46672783
Alanine aminotransferase increased	20.13	17.98	63	13187	88388	46584424
Cholestasis	20.10	17.98	31	13219	26862	46645950
Sinusitis	19.98	17.98	6	13244	129762	46543050
Enterococcal sepsis	19.86	17.98	9	13241	1331	46671481
Staphylococcal infection	19.75	17.98	36	13214	35735	46637077
Depression	19.62	17.98	12	13238	170092	46502720
Laryngeal inflammation	19.43	17.98	5	13245	129	46672683
Rash maculo-papular	19.27	17.98	31	13219	27843	46644969
Bone marrow failure	19.16	17.98	32	13218	29637	46643175
Thrombotic microangiopathy	18.95	17.98	17	13233	8289	46664523
Leukocytosis	18.95	17.98	28	13222	23370	46649442
Electrocardiogram T wave alternans	18.91	17.98	4	13246	42	46672770
Mucosal inflammation	18.76	17.98	37	13213	38939	46633873
Lymphatic disorder	18.76	17.98	6	13244	341	46672471
Tonsillitis bacterial	18.71	17.98	5	13245	150	46672662
Drug-induced liver injury	18.62	17.98	29	13221	25339	46647473
Tinea versicolour	18.58	17.98	4	13246	46	46672766
Pseudomonas infection	18.47	17.98	18	13232	9740	46663072
Factor V inhibition	18.34	17.98	5	13245	162	46672650
Neutropenic colitis	18.23	17.98	10	13240	2222	46670590
Serotonin syndrome	18.22	17.98	28	13222	24192	46648620
Subdiaphragmatic abscess	17.99	17.98	4	13246	54	46672758

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	253.32	15.70	312	17277	106381	29828508
Encephalopathy	209.77	15.70	164	17425	32041	29902848
Acute kidney injury	154.84	15.70	429	17160	273413	29661476
Neurotoxicity	143.67	15.70	92	17497	13090	29921799
Cytokine release syndrome	138.10	15.70	81	17508	9852	29925037
Septic shock	107.64	15.70	158	17431	63449	29871440
Multiple organ dysfunction syndrome	90.93	15.70	146	17443	63341	29871548
Pyrexia	90.16	15.70	376	17213	294113	29640776
Respiratory failure	89.13	15.70	188	17401	100454	29834435
Acute generalised exanthematous pustulosis	80.23	15.70	48	17541	6050	29928839
Sepsis	73.21	15.70	220	17369	146175	29788714
Myoclonus	72.23	15.70	61	17528	13251	29921638
Renal tubular necrosis	67.00	15.70	62	17527	15189	29919700
Fatigue	62.49	15.70	58	17531	320615	29614274
Tubulointerstitial nephritis	60.43	15.70	63	17526	17828	29917061
Hypoxia	60.36	15.70	104	17485	47750	29887139
Neutrophil count decreased	58.51	15.70	96	17493	42358	29892531
Enterococcal infection	55.89	15.70	43	17546	8181	29926708
Mental status changes	55.41	15.70	87	17502	36992	29897897
Neutropenia	54.88	15.70	183	17406	128357	29806532
Clostridium difficile colitis	52.42	15.70	50	17539	12718	29922171
Pathogen resistance	50.75	15.70	41	17548	8369	29926520
Dizziness	50.15	15.70	26	17563	194883	29740006
Status epilepticus	46.68	15.70	44	17545	11028	29923861
Drug reaction with eosinophilia and systemic symptoms	45.58	15.70	69	17520	28419	29906470
Meningitis candida	43.53	15.70	10	17579	71	29934818
Brain herniation	42.96	15.70	27	17562	3713	29931176
Product dose omission issue	42.22	15.70	3	17586	91628	29843261
Myocardial infarction	41.95	15.70	11	17578	125614	29809275
Disseminated intravascular coagulation	41.73	15.70	58	17531	22113	29912776
Death	41.54	15.70	93	17496	357190	29577699
Haemodialysis	41.03	15.70	41	17548	11032	29923857
Bacteraemia	37.53	15.70	46	17543	15514	29919375
Platelet count decreased	37.44	15.70	142	17447	105987	29828902
Pseudomonas infection	37.35	15.70	38	17551	10444	29924445
Methaemoglobinaemia	36.27	15.70	21	17568	2489	29932400
Glomerulosclerosis	36.16	15.70	14	17575	668	29934221
Botulism	34.08	15.70	10	17579	200	29934689
Immune effector cell-associated neurotoxicity syndrome	33.08	15.70	14	17575	842	29934047
Aspergillus infection	32.76	15.70	35	17554	10179	29924710
White blood cell count decreased	31.83	15.70	115	17474	83832	29851057
Fall	31.80	15.70	36	17553	181836	29753053
Enterocolitis	30.95	15.70	28	17561	6659	29928230
Cytomegalovirus enterocolitis	30.03	15.70	13	17576	827	29934062
Blood culture positive	29.72	15.70	24	17565	4895	29929994
Arthralgia	29.51	15.70	22	17567	135769	29799120
Systemic candida	29.37	15.70	19	17570	2745	29932144
Pneumonia	28.78	15.70	311	17278	333995	29600894
Depression	28.19	15.70	9	17580	90428	29844461
Metabolic encephalopathy	28.15	15.70	21	17568	3814	29931075
Eosinophilia	27.70	15.70	48	17541	22112	29912777
Bronchopulmonary aspergillosis	27.51	15.70	35	17554	12249	29922640
Thrombocytopenia	27.23	15.70	155	17434	136889	29798000
Pain	27.20	15.70	37	17552	172604	29762285
Uraemic encephalopathy	27.16	15.70	9	17580	272	29934617
Toxic encephalopathy	26.82	15.70	22	17567	4587	29930302
Nephropathy toxic	26.54	15.70	32	17557	10607	29924282
Pleural effusion	26.01	15.70	99	17490	73967	29860922
Aspartate aminotransferase increased	25.85	15.70	89	17500	63333	29871556
Antibiotic level above therapeutic	24.89	15.70	8	17581	219	29934670
Fungal infection	24.72	15.70	35	17554	13565	29921324
Transaminases increased	24.49	15.70	47	17542	23410	29911479
Drug resistance	24.37	15.70	43	17546	20090	29914799
Candida infection	24.26	15.70	37	17552	15325	29919564
Malaise	24.13	15.70	38	17551	166924	29767965
Cytokine storm	24.07	15.70	10	17579	574	29934315
Red man syndrome	23.75	15.70	11	17578	821	29934068
Clostridium difficile infection	23.51	15.70	37	17552	15746	29919143
Confusional state	23.26	15.70	147	17442	134687	29800202
Acute respiratory distress syndrome	23.25	15.70	46	17543	23426	29911463
Insomnia	23.15	15.70	13	17576	93323	29841566
Anxiety	23.05	15.70	12	17577	89859	29845030
Cytomegalovirus viraemia	22.69	15.70	22	17567	5707	29929182
Acute myeloid leukaemia recurrent	22.47	15.70	13	17576	1539	29933350
Choluria	22.46	15.70	7	17582	173	29934716
Gait disturbance	22.33	15.70	8	17581	74769	29860120
Mucormycosis	22.32	15.70	21	17568	5247	29929642
Dyspnoea	21.97	15.70	111	17478	333184	29601705
Flavobacterium infection	21.88	15.70	6	17583	93	29934796
Headache	21.47	15.70	47	17542	182259	29752630
Pneumonia bacterial	21.39	15.70	27	17562	9376	29925513
Kidney fibrosis	21.34	15.70	14	17575	2071	29932818
Myelodysplastic syndrome	21.32	15.70	39	17550	18739	29916150
Toxic epidermal necrolysis	21.31	15.70	38	17551	17902	29916987
Peripheral swelling	21.04	15.70	5	17584	61069	29873820
Blood pressure increased	20.96	15.70	8	17581	71920	29862969
Immune thrombocytopenia	20.87	15.70	24	17565	7567	29927322
Procalcitonin increased	20.67	15.70	11	17578	1107	29933782
Septic embolus	20.51	15.70	11	17578	1124	29933765
Aphasia	20.35	15.70	39	17550	19400	29915489
Alanine aminotransferase increased	20.35	15.70	92	17497	74184	29860705
Hypersensitivity vasculitis	20.06	15.70	17	17572	3706	29931183
Asthenia	20.04	15.70	65	17524	221225	29713664
Blood creatinine increased	19.90	15.70	106	17483	91269	29843620
Trichosporon infection	19.79	15.70	9	17580	644	29934245
Respiratory distress	19.76	15.70	53	17536	32919	29901970
Staphylococcal sepsis	19.63	15.70	26	17563	9465	29925424
Bacterial toxaemia	19.62	15.70	6	17583	139	29934750
Aeromonas infection	19.26	15.70	7	17582	280	29934609
Blastomycosis	19.09	15.70	7	17582	287	29934602
Renal failure	18.87	15.70	135	17454	128831	29806058
Feeling abnormal	18.87	15.70	5	17584	56751	29878138
Pancytopenia	18.75	15.70	99	17490	84953	29849936
Cerebral aspergillosis	18.67	15.70	11	17578	1347	29933542
Pulmonary haemorrhage	18.31	15.70	25	17564	9367	29925522
Eye infection fungal	18.30	15.70	7	17582	323	29934566
Acute lymphocytic leukaemia recurrent	18.24	15.70	14	17575	2653	29932236
Hypercapnia	17.67	15.70	16	17573	3808	29931081
Retinal ischaemia	17.49	15.70	7	17582	365	29934524
Intracranial mass	17.38	15.70	10	17579	1171	29933718
Drug intolerance	17.07	15.70	3	17586	45288	29889601
Drug level increased	17.02	15.70	35	17554	18319	29916570
Cholestatic liver injury	17.00	15.70	11	17578	1590	29933299
Dysbiosis	16.93	15.70	7	17582	397	29934492
Cholestasis	16.90	15.70	42	17547	24908	29909981
Weight decreased	16.87	15.70	40	17549	150881	29784008
Rash morbilliform	16.82	15.70	13	17576	2489	29932400
Hospitalisation	16.56	15.70	3	17586	44316	29890573
Vanishing bile duct syndrome	16.52	15.70	8	17581	660	29934229
Nasopharyngitis	16.40	15.70	7	17582	58842	29876047
Unresponsive to stimuli	16.37	15.70	43	17546	26376	29908513
Adenoviral haemorrhagic cystitis	16.35	15.70	7	17582	433	29934456
Necrotising retinitis	15.89	15.70	8	17581	717	29934172

Pharmacologic Action:

Source	Code	Description
ATC	J01DE01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Fourth-generation cephalosporins
ATC	J01RA06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:36047	antibacterial drugs

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Infection due to Pseudomonas aeruginosa	indication	11218009
Pneumonia due to Streptococcus	indication	34020007
Pneumonia due to Pseudomonas	indication	41381004
Bacterial pneumonia	indication	53084003	DOID:874
Klebsiella cystitis	indication	60867007
Infectious disease of abdomen	indication	128070006
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Bacterial peritonitis	indication	197171003
Pneumococcal pneumonia	indication	233607000
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Bacterial urinary infection	indication	312124009
Infection due to Staphylococcus aureus	indication	406602003
Urinary tract infection caused by Klebsiella	indication	369001000119100
Complicated Proteus UTI	indication
E. Coli Pyelonephritis	indication
Complicated Urinary Tract Infections	indication
Complicated Bacteroides Peritonitis	indication
Complicated Streptococcus Peritonitis	indication
Klebsiella Pyelonephritis	indication
Complicated E. Coli Peritonitis	indication
Enterobacter Pneumonia	indication
Complicated Klebsiella Peritonitis	indication
Proteus Pyelonephritis	indication
Myoclonus	contraindication	17450006
Colitis	contraindication	64226004	DOID:0060180
Blood coagulation disorder	contraindication	64779008	DOID:1247
Factor II deficiency	contraindication	73975000
Disorder of brain	contraindication	81308009	DOID:936
Seizure disorder	contraindication	128613002
Impaired renal function disorder	contraindication	197663003
Pseudomembranous enterocolitis	contraindication	397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.32	acidic
pKa2	13.31	acidic
pKa3	3.1	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme		DACA_ECOLI DACB_ECOLI DACC_ECOLI FTSI_ECOLI PBP2_ECOLI PBPA_ECOLI PBPB_ECOLI	INHIBITOR				CHEMBL	CHEMBL

External reference:

ID	Source
4024049	VUID
N0000022054	NUI
D01157	KEGG_DRUG
123171-59-5	SECONDARY_CAS_RN
4020908	VANDF
4024049	VANDF
C0055003	UMLSCUI
CHEBI:478164	CHEBI
9WT	PDB_CHEM_ID
CHEMBL186	ChEMBL_ID
CHEMBL1200962	ChEMBL_ID
DB01413	DRUGBANK_ID
D000077723	MESH_DESCRIPTOR_UI
6092	INN_ID
2622	PUBCHEM_CID
10772	IUPHAR_LIGAND_ID
807PW4VQE3	UNII
20481	RXNORM
116681	MMSL
4373	MMSL
d03882	MMSL
004974	NDDF
004975	NDDF
370370003	SNOMEDCT_US
370371004	SNOMEDCT_US
96048006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CEFEPIME HYDROCHLORIDE AND DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3193	INJECTION, SOLUTION	1 g	INTRAVENOUS	NDA	29 sections
CEFEPIME HYDROCHLORIDE AND DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3195	INJECTION, SOLUTION	2 g	INTRAVENOUS	NDA	29 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1301	INJECTION, SOLUTION	1 g	INTRAVENOUS	NDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9566	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	27 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9735	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	27 sections
Cefepime Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3222	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	27 sections
Cefepime Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3223	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	27 sections
cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-121	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	30 sections
cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-121	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	30 sections
cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-122	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	30 sections
cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-122	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	30 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-130	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	27 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-131	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	27 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-240	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	27 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-241	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	27 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6144	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6145	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6146	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6147	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	63323-326	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	27 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	63323-340	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	27 sections
CEFEPIME	HUMAN PRESCRIPTION DRUG LABEL	1	66288-8100	INJECTION, POWDER, FOR SOLUTION	100 g	INTRAVENOUS	ANDA	18 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	66794-209	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	17 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	66794-210	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	17 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	67184-1002	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	67184-1003	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	67184-1004	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	71288-008	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	30 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	71288-009	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	30 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	71288-020	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	30 sections